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1.1. Consumer Cannabidiol (CBD) products (i.e. CBD products which are not licensed 
medicines and which are available to purchase online or on the high street) are sold 
for their potential to produce ‘wellbeing’ benefits (Chesney, McGuire, Freeman, 
Strang, & Englund, 2020). CBD is a non-controlled cannabinoid present in Cannabis 
plant extracts. Currently the most commonly sold CBD product is CBD oil, however, 
the range of products containing CBD is expanding and includes food supplements, 
drinks, cosmetics and liquids for vaping. Consumer interest in CBD is growing 
(European Monitoring Centre for Drugs and Drug Addiction, 2019).  
  
1.2. At present the CBD within these products is derived primarily from the plant 
Cannabis. Due to difficulties in isolating CBD from other cannabinoids, consumer 
CBD products also contain varying amounts of trans-delta-9-tetrahydrocannabinol-
C5 (∆9-THC) and other cannabinoids present in Cannabis that are controlled under 
the Misuse of Drugs Act 1971 (MDA). 
 
1.3. In January 2021, the Home Office stated its intention to establish a legal framework 
for consumer CBD products in a commissioning letter to the ACMD.   
 
1.4. The ministerial commission has sought advice from the ACMD, specifically on:  
 
1.4.1. The maximum dose for any non-negligible effect for ∆9-THC, THCV and CBN 
and the cannabinoid ∆9-THCA-A; 
1.4.2. Whether such products would be liable to be abused or have ill-effects; 
1.4.3. Whether the controlled substances, in practice, can be recovered from such 
products; 
1.4.4. The current analytical capability to test for cannabinoid content; 
1.4.5. How the exempt product definition in the MDR may be amended to apply only 
to diagnostic equipment, or for scientific research, as originally intended.  
(Note: this part of the commission will be considered in a separate piece of 
advice).  
 
1.5. To respond to this commission, the ACMD formed a Working Group who have 
reviewed the literature, consulted with industry and analytical laboratories, and 
issued a public call for evidence.  
 
1.6. This report will not evaluate the effectiveness of CBD products. Nor will it re-
evaluate the potential harms of any of the controlled cannabinoids, nor make 
comment about their classification or schedule. This report will consider the dose at 
which cannabinoids have no detectable psychoactive effect on humans (i.e. for the 
purposes of this report, dose means amount in grams), the analytical capabilities to 
test for these cannabinoids, and the feasibility of production of consumer CBD 
products with low levels of controlled cannabinoids. The intention being to give 
consideration to consumer CBD products derived from extracts of Cannabis rather 







2.1. Plants of the genus Cannabis contain multiple naturally occurring cannabinoids that 
are referred to as ‘phytocannabinoids’. Twelve phytocannabinoids are controlled 
under the MDA. The main psychoactive phytocannabinoid is ∆9-THC, commonly 
known as THC, which acts as a partial agonist at the cannabinoid type-1 receptor 
(CB1 receptor) in the brain. For a review of the control status of phytocannabinoids, 
please refer to Table 1 from ACMD’s 2016 report on Phytocannabinoids (ACMD, 
2016). 
 
2.2. Phytocannabinoids such as cannabidiol (CBD), that have low affinity for the 
orthosteric (agonist) binding site on the CB1 receptor, are not controlled. CBD has 
been reported to act as a negative allosteric modulator at CB1 and CB2 receptors, 
reducing the response to agonists such as ∆9-THC (Laprairie, Bagher, Kelly, & 
Denovan-Wright, 2015), (Tham, et al., 2019). 
 
 
2.3. The CBD that is used in consumer products is mainly extracted from Cannabis 
flower and leaves and the resulting product referred to as ‘CBD isolate’. Whilst trying 
to maximise the CBD content of the isolate it still contains other phytocannabinoids 
including those that are controlled. Throughout this report ‘CBD isolate’ will refer to 
this extracted product. In the UK, a Schedule 1 controlled drugs licence is required 
to grow Cannabis, irrespective of the THC content of the plant. To lawfully use the 
controlled parts of the plant (the flower and leaves) licensing permissions to enable 
possession, production and potentially supply of ‘Schedule 1’ material would be 
required as the possession of harvested material from controlled parts of the plant 
would be unlawful without a licence.  
 
 
2.4. CBD can also be produced by chemical synthesis (Jung et al., 2019). As the 
popularity of consumer CBD products increases, the demand for synthetic CBD is 
likely to increase and improved methods developed (Bloemendal et al., 2021). 
Commercially produced synthetic CBD may however still be contaminated with ∆9-
THC (Grubb, 2020). The Working Group therefore decided that for the time being 
the regulations relating to the levels of controlled phytocannabinoids in CBD 
consumer products should apply whether the origin of the CBD is by extraction from 
the Cannabis plant or by chemical synthesis. 
 
 
2.5. To obtain a controlled drug from another country an import licence must be obtained 
from the Home Office. This is to enable the UK government to keep records of such 
transactions for reporting purposes and remain compliant with their international 
obligations to the International Narcotics Control Board (INCB). 
 
 
2.6. Within the MDR there is an exempt product definition that excludes products from 
control if they meet all of the 3 criteria required for exemption (UK Legislation, 
2001). Companies which market consumer CBD products often claim their products 
meet all of the 3 criteria and are therefore exempted from control under the MDA. 
This commission also asked for the ACMD to reword the exempt product definition 
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to apply only to diagnostic equipment or for scientific research, thereby 
unambiguously excluding consumer products and any products intended for human 




2.7. The industrial hemp industry in the UK, under the requisite licence, grows low-∆9-
THC content Cannabis or ‘hemp’ for fibre and seed (under the stipulations of the 
Industrial Hemp Licence all controlled parts of the plant must be destroyed). The 
farmed components have various industrial uses, such as the processing of the 
seeds to make cold pressed hemp seed oils (as distinct from CBD oil) and using the 
fibre to produce clothing or rope.  
 
 
2.8. Hemp production for use of the uncontrolled fibre and seed is considered under a 
different policy and licensing regime to a Cannabis Cultivation licence for use of the 
controlled parts of the plant which are required for CBD production. There is a 
misconception amongst some members of the consumer CBD product industry that 
consumer CBD products are legal if they contain less than 0.2% ∆9-THC. This 
misunderstanding may arise from an incorrect interpretation of the wording within 
the Misuse of Drugs (Licence Fees) Regulations 2010. A licenced grower of hemp 
must only cultivate a Cannabis strain that is on the approved seed type list and 
contains less than 0.2% ∆9-THC to meet the requirements of that licence. This 
licence only allows for the use of uncontrolled parts of the Cannabis plant and 
therefore should not be used to cultivate material for any other purpose including 
creating CBD isolate.  
 
 
2.9. The relatively unregulated nature of the consumer CBD product market has meant 
that the actual levels of ∆9-THC in different products from different suppliers vary 
dramatically. A Defence Science and Technology Laboratory (Dstl) investigation into 
forty-three commercial CBD products available in the UK found sixteen (37%) 
contained more than 5 mg of ∆9-THC (Defence Science and Technology Laboratory 
report, 2020a). For context 5 mg ∆9-THC is one standard THC unit – a low dose that 
can produce mild psychoactive effects similar to a standard alcohol unit (Freeman & 
Lorenzetti, 2020). Similar variability in the CBD and ∆9-THC content of consumer 
CBD products available in the UK, Europe and the USA have been reported in the 
scientific literature (Pavlovic, et al., 2018), (Lachenmeier, et al., 2019), (Dubrow, et 
al., 2021), (Liebling et al., 2020). 
 
 
2.10. Health food shops in the UK currently sell CBD capsules and edible products 
ranging from 5 to 20 mg per dose, and oils and sprays from 2 to 8 mg per dose 
(Chesney, McGuire, Freeman, Strang, & Englund, 2020). The Food Standards 
Agency recommended the level of safe consumption to be 70 mg/day (Food 
Standards Agency, 2020). 
 
 
2.11. The ACMD has consulted with the National Police Chiefs’ Council (NPCC), who 
reported that there has been no evidence to date of diversion of consumer CBD 
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products or extraction from such products of ∆9-THC or other controlled 
phytocannabinoids. The Working Group highlights that in addition to the lack of 
evidence, it would be highly unlikely that consumers would seek to use CBD 
products for the psychoactive effects of ∆9-THC, due to the very low levels of ∆9-
THC present in such products. 
 
 
2.12. In this report, levels of phytocannabinoids at which a user may experience 
noticeable psychoactive effects will be discussed. Within the scientific literature the 
term ‘intoxication’ would typically be used, with the term ‘psychoactive’ having 
multiple different uses and the term ‘psychotropic’ having medicinal connotations. 
Within legislation the UN use the term ‘psychotropic’ in their Convention on 
Psychotropic Substances 1971, whereas the UK have used ‘psychoactive’ in the 
Psychoactive Substances Act 2016 (PSA). Whilst ‘intoxication’ might be scientifically 
correct, it has negative connotations in the public sphere and so the report 
throughout will use the term ‘psychoactive’ to refer to the effects of these drugs as it 
most closely aligns with other UK legislation. 
 
 
2.13. When defining the levels of substances within products there are different measures 
that can be used. In this report the levels of phytocannabinoids within a product (no 
matter what product) are given in the form of the weight in grams or the weight of 
the substance as a percentage of the weight of the total product (i.e. % w/w). For 
consistency, when referring to products that are liquids this report will still use % 
w/w, not weight by volume (i.e. % w/v). Amongst consumer CBD product producers 
it is common practice when giving the levels of controlled phytocannabinoids such 
as ∆9-THC in CBD products to indicate the amount of ∆9-THC as a percentage of 
the weight of CBD in the product (i.e. the ratio of % weight ∆9-THC to weight of 
CBD). However, to avoid any confusion, this report will only use weight of the 
substance as a percentage of the weight of the product in which it is contained 
unless specifically stated otherwise.   
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3. Controlled Phytocannabinoids 
3.1. Phytocannabinoids are controlled using generic definitions within the MDA. The 
ACMD’s Phytocannabinoids report (ACMD, 2016) identified 12 phytocannabinoids 
that would be considered controlled under the MDA. These are detailed in Annex D. 
 
3.2. Since the last review of phytocannabinoids (ACMD, 2016) two further analogues 
substituted at the 3-position of trans-(-)-∆9-THC with slightly more extended alkyl 
chains have been described (tetrahydrocannabiphorol [THCP, 3-heptyl] (Citti, et al., 
2019) and tetrahydrocannabihexol [THCH, 3-hexyl] (Linciano, et al., 2019). Their 
psychoactivity in humans has not been reported, although structure-activity 
considerations suggest that they are likely to have activity as CB1 agonists. The fact 
that they have only recently been identified may be taken as an indication of their 
low abundance.  
 
 
3.3. While there is some evidence from human and animal studies that CBD can 
attenuate or exacerbate the behavioural and cognitive effects of ∆9-THC, these 
observations have not been consistently reported and may only occur at doses of 
CBD higher than those available from consumer CBD products (Englund, et al., 
2013). Furthermore, there is at present no firm evidence for minor 
phytocannabinoids or terpenoids present in preparations of Cannabis acting 
synergistically to enhance the effects of ∆9-THC nor interacting with CBD to elicit an 
acute psychoactive effect (Chesney, McGuire, Freeman, Strang, & Englund, 2020), 
(Finlay, Sircombe, Nimick, Jones, & Glass, 2020), (Santiago, Sachdev, Arnold, 




3.4. In this report the term ‘precursor’ is used simply to describe chemical compounds in 
the Cannabis plant that are converted naturally into phytocannabinoids. This does 
not come under precursor chemical licencing controls of illicit synthesis of controlled 
drugs. 
 
3.5. The Cannabis plant generates several acidic phytocannabinoid precursors (Wang, 
et al., 2016). In fresh Cannabis ∆9-THC, CBD, and CBC exist as their acidic 
(carboxylated) precursors (Wang, et al., 2016), (Tahir, Shahbazi, Rondeau-Gagné, 
& Trant, 2021). Two ∆9- THC precursors have been identified in the plant (2-
carboxyl ∆9-THC, referred to as ∆9-THCA-A, and 4-carboxyl ∆9-THC, referred to as 
∆9-THCA-B). The more abundant form being ∆9-THCA-A which has only weak 
agonist activity at CB1 and CB2 receptors (McPartland, et al., 2017).  Hereinafter, 
unless specifically identified, these two precursors are combined and referred to as 
∆9-THCA. There is no indication of ∆9-THCA being converted to ∆9-THC to any 
significant degree within the body after ingestion. 
 
 
3.6. Conversion of acid precursors to corresponding THC analogues is achieved by 
heating. Whilst precursor acids can be converted to phytocannabinoids at 
temperatures of less than 100 oC, a much longer duration is needed for this 
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conversion to occur without heating (Wang, et al., 2016). Conversion is more rapid 
at elevated temperatures. It is anticipated that at room temperature, conversion of 
THCA to THC analogues is negligible. 
 
 
3.7. Measurements intended to indicate the psychoactive potency of Cannabis-derived 
materials usually include both the amount of ∆9-THC and the amount of ∆9-THCA to 
address the potential for conversion of ∆9-THCA to ∆9-THC in storage and by 
heating. The total ∆9-THC content (∆9-THC plus ∆9-THCA) is calculated within US 
legislation by applying a conversion factor of 0.877 to allow for the percentage of the 
weight of ∆9-THCA, which is lost in the decarboxylation process based on the 
molecular weights of the two materials (US legislation, 2018). 
 
 
3.8. Legally precursors are not controlled within the MDA or MDR, however, in this report 




3.9. Phytocannabinoids are structurally related compounds with the potential in some 
cases for chemical conversion from one to another. With the exception of precursor 
acids (discussed above) it is very unlikely that most non-psychoactive 
phytocannabinoids are converted into psychoactive ones except under laboratory 
conditions.  
 
3.10. CBD can be converted to ∆9-THC under acid and heat conditions or utilising more 
specialised laboratory reagents to achieve the cyclisation. Whether such conversion 
occurs in the acidic contents of the stomach following oral administration has been 
the subject of much experimentation and debate (Golombek, Müller, Barthlott, 
Sproll, & Lachenmeier, 2020). At present no definitive answer is available. 
 
 
3.11. ∆9-THC can be converted to cannabinol-C5 (CBN). This may be relevant to the 
storage of CBD products, especially when they are exposed to air and humidity 
(Pavlovic, et al., 2018), (Citti, et al., 2019). CBN is less potent than ∆9-THC in 
producing psychoactive effects (Perez-Reyes M., Timmons, Davis, & Wall, 1973)  
and has been reported to be present at lower levels than ∆9-THC in CBD products 




3.12. In addition to the oral route of administration, some consumer CBD products may be 
inhaled following vaporization or smoking. These include CBD vape-liquids and 
herbal CBD products such as “Cannabis light” (Cas, et al., 2020). Inhalation of ∆9-
THC produces similar psychoactive effects following either vaporization or smoking 
(Abrams, et al., 2007) (Newmeyer, Swortwood, Abulseoud, & Huestis, 2017). In a 
recent study, it was reported that under oxidative conditions CBD could be 
converted to ∆9-THC by heating (Czégény, et al., 2021). However, it is not known at 
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present if CBD would be converted to ∆9-THC when dissolved in liquids containing 




3.13. The ACMD’s Phytocannabinoids report (ACMD, 2016) found sufficient evidence to 
determine the psychoactivity of ∆9-THC, delta-8-tetrahydrocannabinol (∆8-THC) and 
CBN. It was unsure about the psychoactivity of delta-9-tetrahydrocannabivarin 
(THCV). For the remaining 8 controlled phytocannabinoids there was not sufficient 
evidence to determine psychoactivity. Here the potential threshold dose that is 
unlikely to produce any psychoactive effect for ∆9-THC, ∆8-THC, THCV and CBN, is 
considered. 
 
3.14. Most phytocannabinoid research has focused on ∆9-THC or CBD, with limited 





3.15. Experimental psychopharmacology studies in humans have found that acute 
administration of ∆9-THC can produce psychoactive effects at single oral doses as 
low as 2.5 – 5 mg (Haney, 2007), (Ballard & Wit, 2011), (Chesher, Bird, Jackson, 
Perrignon, & Starmer, 1990), (Beal, et al., 1995), (Beal, et al., 1997).  
 
3.16. It has been reported that single inhaled doses of ∆9-THC as low as 2 mg can 
produce psychoactive effects (Zuurman, et al., 2008), (Klumpers, et al., 2012). 
There is a lack of studies testing the effects of single inhaled doses of ∆9-THC lower 
than 2 mg. 
 
 
3.17. The peak level of subjective effects from ∆9-THC are similar for oral, smoked and 
vaporized administration of the same dose of ∆9-THC among infrequent Cannabis 
users, but oral administration results in slower onset and longer duration of effects 
(Newmeyer, Swortwood, Abulseoud & Huestis, 2017). 
 
 





3.19. Whilst the ACMD Phytocannabinoids report found ∆8-THC to be psychoactive, there 
was not sufficient evidence in humans to establish a threshold dose for 
psychoactive effects. However, there is a single report from the 1970s that suggests 
the potency both orally and intravenously of ∆8-THC is similar to ∆9-THC (Hollister & 





3.20. The disputed potential psychoactivity of THCV motivated the 2016 report into 
phytocannabinoids (ACMD, 2016). That report concluded that the psychoactivity of 
THCV had not been determined.  
 
3.21. Two studies found that a single oral dose of 10 mg THCV produced no detectable 
subjective effects (Tudge, Williams, Cowen & McCabe, 2015), (Rzepa, Tudge & 
McCabe, 2016). When administered orally for five sequential days, 10 mg THCV 





3.22. Oral administration of CBN produced no psychoactive effects at a dose of 50 mg 
(Karniol, Shirakawa, Takahashi, Knobel & Musty, 1975). A study comparing single 
intravenous doses of ∆9-THC, CBN and CBD found that the dose of CBN required to 
produce subjective psychoactive effects was over 10-fold higher than that for ∆9-




3.23. While the precise thresholds for psychoactive effects from ∆8-THC, THCV and CBN 
may not be possible to estimate, it can be concluded with reasonable certainty that 
the threshold dose for THCV and CBN would be substantially higher than the 
threshold for ∆9-THC, with that for ∆8-THC being unknown.  
 
3.24. Cannabis in its various forms (leaf, flower, resin and extracts) is an exceptionally 
complex matrix comprising hundreds of phytochemicals, of which the cannabinoids 
(CBD, ∆9-THC, CBG, CBC, ∆8-THC, CBN, THCV) are also extremely variable in 
terms of their concentrations (Kinghorn, Falk, Gibbons & Kobayashi, 2017). 
However, while the concentration of ∆9-THC in Cannabis plant samples may be 
typically in the region of 15-20% the other controlled phytocannabinoids are present 
in very low concentrations e.g. <0.1% for THCV; <0.1% ∆8-THC; <1% for CBN 
(Chandra, et al., 2019).  
 
3.25. The Working Group concluded that it is very unlikely that plant-derived consumer 
CBD products would contain sufficient controlled phytocannabinoids (apart from ∆9-
THC) to produce any pronounced psychoactive effects unless they were purposely 




4. Analytical Techniques 
4.1. Measurement of levels of controlled phytocannabinoids in consumer CBD products 
comprises three stages. 
 
4.1.1. Extraction of the phytocannabinoids from the product matrix into a 
suitable solvent compatible with the analytical method to be used. 
 
4.1.2. Separation of the phytocannabinoids from each other and from other 
non-phytocannabinoid compounds in the extract. This is normally 
performed by gas chromatographic (GC) or liquid chromatographic (LC) 
techniques. GC involves heating the sample and this will convert 
thermally labile precursor acids to active phytocannabinoids. LC does not 
involve high temperatures and so preserves thermally labile compounds. 
 
 
4.1.3. Detection and quantification of the amount of each phytocannabinoid. 
There are various techniques used for detection which differ in their 
sensitivity (see Annex C). Quantification of the amount of each 




4.2. The commonly used methods of separation and detection have recently been 
reviewed by the Defence Science and Technology Laboratory (Defence Science 
and Technology Laboratory report, 2020b). The advantages, disadvantages and 
Limit of Quantification (LoQ) of each technique are summarised with descriptions in 
Annex C. Mass spectrometry (MS) or tandem mass spectrometry (MS-MS) offer the 
most sensitive methods for quantification but are also the most expensive to 
perform. 
 
4.3. Accurate measurement of phytocannabinoids depends both on the resolution of the 
separation method and the selectivity of the detection method. GC with flame 
ionisation detection or LC with UV detection have low specificity and therefore if ∆9-
THC and other trace phytocannabinoids are not completely separated from one 
another and from other substances in the extract then coelution with interfering 
substances may increase the detector response causing an overestimate of the 
analyte concentration. This can largely be overcome by use of a more selective 
detector such as MS or MS-MS which can usually be set to only respond to the 
analyte of interest even if it coelutes with another substance. 
 
4.4. In order to comply with any specified limits for the concentrations of ∆9-THC and 
other controlled phytocannabinoids in consumer CBD products the analytical 
method must be capable of detecting and quantifying these substances at 
concentrations below the specified limits.  Using a method with insufficient 
sensitivity and obtaining a negative result does not prove that the phytocannabinoid 




Testing capability and reliability 
 
4.5. In early 2021, an inter laboratory comparison trial (referred to as a ‘ring-trial’) 
sponsored by a number of government departments and devolved administrations, 
and co-ordinated by the Government Chemist’s Team was run to assess the 
capability of analytical laboratories (based in UK and elsewhere) to undertake the 
analysis of consumer CBD products for the presence of CBD and other 
phytocannabinoids, including ∆9-THC, ∆9-THCA-A, ∆8-THC, CBN and THCV 
(Government Chemist’s Team, 2021).  While the full report is available online, below 
we provide a brief summary.  
 
4.5.1. A set of three commercially available consumer CBD products, an oil, a spray 
and a body wash, was circulated to the participating laboratories and the 
analytical findings returned were evaluated. The participating laboratories used 
a variety of analytical techniques and protocols. The trial established that while 
the majority of the laboratories were able to produce satisfactory results for the 
amount of CBD in the products supplied, the results for other controlled 
phytocannabinoids, which were present in the samples at lower concentrations, 
were more varied. A number of participating laboratories were either unable to 
detect or to reliably quantitate some or all of the other phytocannabinoids of 
interest.   
 
4.5.2. The trial identified the need to apply advanced analytical techniques, such as 
LC-MS/MS, in order to achieve the sensitivity necessary to quantitate accurately 
the controlled phytocannabinoids present in CBD products. The use of 
appropriate internal standards, such as stable isotope labelled versions of the 




4.5.3. Application of the sensitive methodology suggested by the ring-trial 
evaluation, preferably combined with independently assessed quality assurance 
measures such as proficiency testing and accreditation, would improve the 
analytical reliability that would be necessary to underpin any regulations 
developed to limit the levels of controlled phytocannabinoids in CBD products.  
 
 
4.6. When analysing trace components of complex materials, matrix effects, such as 
those caused by other components co-eluting from the separation stage of the 
analysis with the target species, can be problematic. Therefore, the levels of 
accuracy achieved in laboratories (such as within the Government Chemist’s ring 
trial (Government Chemist’s Team, 2021) may differ from the theoretical maximum 
of these techniques as reviewed in the Dstl report (Defence Science and 
Technology Laboratory report, 2020b). 
 
4.7. The extraction and analysis of trace amounts of phytocannabinoids in consumer 
CBD products is technically challenging. The extraction method and parameters 
used for the method of analysis need to be optimised for each type of product; there 





4.8. The product composition or matrix (this may include oils, fats, sugars, gums, 
particulates etc) can reduce the efficiency of extraction of the controlled 
phytocannabinoids.  The exact chemical composition of the product matrix may not 
be known and therefore it may only be possible to simulate approximately the matrix 
with a similar matrix (for matrix matching). These sample matrix effects necessitate 
the use of extraction methods optimised for each CBD product and the use of an 
internal standard to compensate for any reduction in extraction efficiency.  
 
 
4.9. The CBD isolate used in the production of consumer CBD products contains many 
other compounds present in trace amounts which may interfere with the detection of 
∆9-THC and other controlled phytocannabinoids. CBD itself has a chemical structure 
closely related to those of the controlled phytocannabinoids but is present at a 
concentration several thousands of times higher, which makes it difficult to detect 
the controlled phytocannabinoids at trace levels.  
 
 
4.10. ∆9-THC and other controlled phytocannabinoids at trace levels are also susceptible 




4.11. In addition, analytical uncertainty tends to increase as the concentration of the 
analyte being measured decreases (the ‘Horwitz trumpet’ effect). 
 
 
4.12. Detection and quantification of low levels of ∆9-THC and other controlled 
phytocannabinoids in the presence of CBD within a variety of matrices is analytically 
challenging and use of inadequate analytical procedures could lead to erroneously 
negative findings. 
 
4.13. Quality assurance techniques such as use of appropriate reference materials, 
analysis of control samples and participation in proficiency testing can all help to 
ensure that analyses are valid, and results are dependable.  However, the most 
effective route to be able to demonstrate analytical competence and reliability of 
results is for the analytical processes to be accredited to the international standard, 
ISO 17025, by means of third-party assessment. This addresses aspects such as 
the qualifications, training and experience of the staff, use of appropriate and 
validated testing procedures and equipment which is properly calibrated and 
maintained, adequate quality assurance procedures, proper sampling practices, 
traceability of measurements to national standards, accurate recording and 
reporting procedures and the suitability of testing facilities. 
 
4.14. Laboratories assessing compliance would need to be accredited to the ISO 
standard. Producers should use laboratories which hold that accreditation to 
perform their quality assessment testing.  
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Phytocannabinoid reference standards 
4.15. Chemical reference standards are well characterised substances which can be used 
as points of comparison to support identification and quantitation of target analytes.  
Reference standards produced by suppliers certified to the relevant International 
Standard (ISO Guide 34) provide reliable and traceable reference points. 
  
4.16. Major suppliers of drug-related chemical reference materials provide certified 
reference standards for the most common phytocannabinoids of analytical interest 
such as: ∆9-THC, ∆9-THCA-A, ∆8-THC, THCV, CBD, CBN and CBC. Product ranges 
include stable-isotope labelled versions of THC, CBD and CBN. However, currently 
standards are not commercially available for all of the controlled phytocannabinoids 




5. Interpretation of findings 
 
5.1. The purpose of this report is to recommend appropriate limits on the level of 
controlled phytocannabinoids within consumer CBD products. It is common 
practice for the weight of phytocannabinoids to be reported as a percentage of the 
amount of CBD present. However, the range of consumer products derived from 
Cannabis is rapidly changing, with new products coming to market for the 
consumption of other uncontrolled phytocannabinoids such as cannabichromene 
(CBC) and cannabigerol (CBG). To future proof any legislation, the recommended 
limits of controlled phytocannabinoids in this report are given as weight in grams or 
weight of phytocannabinoid as a percentage of the weight of product. 
  
5.2. In a review of the open literature on the analysis of CBD consumer products Dstl 
collated data (Figure 1) demonstrating a wide range of ∆9-THC content in products 
(Defence Science and Technology Laboratory report, 2020b). 
 
5.3. The variation in the ∆9-THC content within the same types of products (Figure 1) 
likely reflects the unregulated nature of the market. 
  
5.4. From the consultations with industry it is the Working Group’s understanding that 
typical CBD isolate used in the production of CBD products contains 0.02-0.03% 
(% w/w ∆9-THC to CBD i.e. not ∆9-THC as a % weight of product). CBD isolate 
containing lower amounts of ∆9-THC are commercially available (e.g. with 0.005-
0.007% ∆9-THC to CBD) but these are more expensive to produce. 
Figure 1: Bar chart with logarithmic y-axis showing the ranges of Δ9-THC content in different CBD and hemp consumer 
products reported in the open literature.  The top and bottom ends of each bar represent the maximum and minimum 
quantities detected in the samples. Figure reproduced from Defence Science and Technology Laboratory, 2020b © Crown 
Copyright 2020.   
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Controlled phytocannabinoids for which levels should be set 
 
5.5. When considering which phytocannabinoids should have limits set the following 
factors were taken into account: 
  
5.5.1. Levels (relative) found in Cannabis preparations/Cannabis plants. 
 
5.5.2. The potential psychoactive potency of each phytocannabinoid. 
 
As described in Chapter 3, the controlled phytocannabinoids other than ∆9-THC 
are either present in insufficient quantities or are of such low potency that they can 
be considered not to exert any psychoactive effect when present in consumer CBD 
products. Therefore, the Working Group concluded that it was appropriate to set 
specific limits for the content of ∆9-THC and its precursors ∆9-THCA-A and ∆9-
THCA-B in consumer CBD product. 
  
5.6. ∆9-THC and ∆9-THCA (i.e. ∆9-THCA-A and ∆9-THCA-B) are present in CBD 
products. ∆9-THCA can convert to ∆9-THC with heat. Therefore, to control the 
quantity of ∆9-THC the limit should also take into account ∆9-THCA. These two 
compounds can either be measured in a combined manner (when analysis is 
performed using a technique that involved heating such as gas chromatography) 
or separately (when using techniques like liquid chromatography). When measured 
separately, within US legislation (US legislation, 2018), the amounts of each are 
combined to give the total possible ∆9-THC content taking into account their 
relative molecular weights using the following formula 
∆9-THCtotal = ∆9-THCweight + (0.877 x ∆9-THCAweight). 
Equation 1: Formula for total ∆9-THC content 
5.7. However, not setting any limit for the other controlled phytocannabinoids could set 
a precedent whereby a CBD product to which any of these other controlled 
phytocannabinoids had been added (i.e. spiked) might be considered legal. To 
prevent this possibility, it was agreed that the maximum level of each controlled 
cannabinoid should be the same as ∆9-THC + ∆9-THCA. 
 
5.8. Whilst the other controlled cannabinoids do have precursor acids, they are present 
in low amounts. The need to measure these could become burdensome upon 
producers. Therefore, it was decided not to recommend controlling these at 
present.  
Determining a maximum dose of ∆9-THC that would not produce a 
psychoactive effect 
 
5.9. In considering what would be the appropriate level for ∆9-THC in commercial CBD 
products we first considered the lowest dose of ∆9-THC that would produce any 
adverse effects (LOAEL). In the written submissions received to our Call for 
Evidence and in international food regulations the recommended LOAEL for ∆9-
THC ranges between 2 – 5 mg/day. This agrees with the experimental studies on 




5.10. The remit of this report was to recommend a ‘low’, trace level for the controlled 
phytocannabinoids in consumer CBD products under the MDA and so 
consideration was given to the maximum dose of ∆9-THC that would be unlikely to 
produce any psychoactive effect (i.e. elevation of mood or ‘high’). The Working 
Group consider that a ∆9-THC dose of 1 milligram (mg) was unlikely to produce 
significant psychoactive effects.  
 
5.11. A major challenge for recommending a single dose level for ∆9-THC is how 
applicable it is to consumer CBD products consumed by different routes of 
administration– oromucosal, oral, inhalation, topical – where the bioavailability, 
rate of absorption and peak levels may be different. In studies of the psychoactive 
effects produced by the same dose of ∆9-THC administered orally or by inhalation 
the peak level of effect was observed to be comparable between the two routes 
(Ohlsson et al.); infrequent users in (Newmeyer, et al.). In the absence of more 
definitive studies on the maximum dose of ∆9-THC that would be unlikely to 
produce any psychoactive effect when given by different routes of administration 
the Working Group propose that 1 mg should apply to all consumer CBD products. 
 
5.12. There is very limited information available on whether young people are more or 
less sensitive to the psychoactive effects of ∆9-THC. In one study comparing the 
acute effects of Cannabis in adolescent (16–17 years old) and adult (24–28 years 
old) male Cannabis users, it was reported that after inhaling vaporized Cannabis, 
adolescents reported fewer psychoactive effects than adults (Mokrysz et al). 
 
5.13. The ACMD has consulted with the National Poisons Information Service who 
report that for consumer CBD products in general episodes of toxicity involving 
children are very rare. 
 
5.14. Two additional uncertainty factors were then applied (Table 1): 
• The first of 10 (to account for differences in age, body size, individual 
variation in response) and, 
• a second of 2 (to take account of variations in use or concurrent use of 
more than one product). 
 
5.16 No uncertainty factor has been applied to account for the possibility of CBD along 
with other cannabinoid and terpenoid compounds that may be present in CBD 
products acting to enhance the actions of ∆9-THC. Studies to date have not 
provided compelling evidence for such an interaction (Chesney, McGuire, 
Freeman, Strang, & Englund, 2020), (Finlay, Sircombe, Nimick, Jones, & Glass, 
2020), (Heblinski, et al., 2020), (Santiago, Sachdev, Arnold, McGregor, & Connor, 


















Non psychoactive dose  
 
1 mg 1 x 10-3 
Reduction by 10x  
(to account for variability in age, body 
size, individual variation in response) 
 
100 µg 1 x 10-4 
Further reduction by 2x  
(to take account of variations in use 
or concurrent use of more than one 
product) 
50 µg 5 x 10-5 
Table 1: Calculation of recommended maximum ∆9-THC dose. 
Setting the defined trace percentage for ∆9-THC in consumer CBD 
products  
5.17. Three approaches to setting the limits for the level (concentration) of controlled 
phytocannabinoids in consumer CBD products were considered, along with their 
advantages and disadvantages. 
 
 Setting a level that would apply to all consumer CBD products 
 
 Setting a level as a percentage of CBD content 
 
 Setting different levels for different CBD products 
 
5.18. Setting a level for controlled phytocannabinoids that would apply to all 
consumer CBD products has the advantage of being the simplest to do in 
legislation. However, it has practical disadvantages.  
 
5.18.1. Due to the differences in product matrix and difficulties in extracting 
phytocannabinoids from different products (see Chapter 4: Analytical Techniques) 
a limit that is practical to test in one product such as a drink might not be practical 
in another such as oil or food. 
  
5.18.2.  There are significant differences in the weight of a typical single serving of 
different products (here the terms ‘unit of consumption’ and ‘single serving’ are 
used to refer to a typical quantity consumed in one occasion, such as drops of oil, 
capsule, bottle or can of drink, or a chocolate bar). To meet the limit set, 
producers of products for which a single serving is of low weight (e.g. oils, 
capsules) would therefore have to use initial CBD isolate of higher purity (lower 
levels of ∆9-THC) than producers of products where the single serving is of higher 
weight (e.g. chocolate bar, drinks) if the final concentration of ∆9-THC has to be 
under the limit set. This would have significant financial implications for 
manufacturers of CBD products that have a low single serving weight as they 




5.19. Setting a level for controlled phytocannabinoids as a percentage of CBD 
content has the advantage of being practical as the ratio of controlled 
phytocannabinoid to CBD content could be determined in the initial isolate. 
However, this method presents three difficulties.  
 
5.19.1. A product with large quantities of controlled phytocannabinoids could be 
produced by increasing the level of CBD.  
 
5.19.2. Separate legislation would be required to limit the content of controlled 
phytocannabinoids in any new consumer products containing uncontrolled 
phytocannabinoids such as CBC or CBG.  
 
5.19.3. In calculating this ratio of ∆9-THC to CBD the error in the estimations of each 
would be compounded when taking the ratio.  
 
5.20. Setting levels for different types of product individually allows for variations in 
weight of single servings of different products and avoids the problems that arise 
when setting one limit across all products as outlined above. Setting levels for the 
controlled phytocannabinoids avoids issues of setting the limit relative to the CBD 
content, though it does mean considerations have to be made to what is feasible 
regarding the sensitivity of the methods used to measure low concentrations of 
phytocannabinoids. The Regulations would be more complex and require product 
by product evaluation but would provide a framework that can be used in future for 
novel products that will require market authorisation. 
 
5.21. Some example limits are calculated below for CBD oil, drinks and chocolate bars 
(Table 2). Given the lack of evidence of the consumption of large amounts of a 
CBD product to obtain the psychoactive effects, the group have calculated limits 
assuming the user consumes a single serving of these products for the claimed 
wellbeing effect. These limits have been calculated on the basis of what the 
Working Group thought was a normal amount to be consumed, however, this has 
been done for illustrative purposes and would need to be performed on a product 
by product basis. 
 






Oil 0.45 (0.5 ml) 1.1 x 10-4 0.011 (1.1 x10-2)  
Drink 524 (500 ml) 9.5 x 10-8 0.0000095 (9.5x10-6)  
Chocolate bar 100  5 x 10-7 0.00005 (5x10-5)  
Table 2: Guide limits for three common consumer CBD products containing 50 micrograms ∆9-THC 
5.22. These typical limits are feasible for industry to achieve using an isolate containing 
0.03% ∆9-THC (as a percentage of CBD content) with the appropriate level of 
dilution. 
  
5.23. Although testing can theoretically achieve a level of quantification of 1.1x10-7 % 
(Defence Science and Technology Laboratory report, 2020b) the current testing 
capacities might not be able to achieve this in all product types (see 4. Analytical 
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Techniques and Annex C). Therefore, there would need to be investment within 






6.1. Extraction of controlled phytocannabinoids from consumer CBD products is unlikely 
to be a viable means of obtaining these drugs for illicit use. 
 
6.2. It would be appropriate to set specific limits for the content of ∆9-THC and its 
precursor ∆9-THCA (i.e. ∆9-THCA-A and ∆9-THCA-B) in consumer CBD products. 
 
6.3. Plant-derived consumer CBD products would not contain sufficient controlled 
phytocannabinoids (other than ∆9-THC) or their precursor acids to produce any 
pronounced psychoactive effects unless they were added to the product (i.e. 
spiked). To prevent the possibility of spiking a limit should be set for all controlled 
phytocannabinoids in consumer CBD products. 
 
6.4. The dose limit for total ∆9-THC (∆9-THC plus ∆9-THCA) should be 50 micrograms 
(µg) in a unit of consumption (where a unit of consumption or ‘single serving’ is the 
typical quantity of a CBD product consumed on one occasion).  
 
6.5. At the recommended levels the controlled phytocannabinoids present in consumer 
CBD products are highly unlikely to produce any harmful effects. 
 
6.6. Setting a single concentration limit that applies to all consumer CBD products would 
not be appropriate.  
 
6.7. Further research is needed to confirm whether conversion of CBD to ∆9-THC by 
extreme heating can occur and its relevance to the processes involved in CBD 
vaping evaluated. 
 
6.8. Currently the methods for extraction, separation and quantification of controlled 
phytocannabinoids in consumer CBD products are not sufficiently robust with 
regards to sensitivity, accuracy and reproducibility. 
 
6.9. Laboratories assessing compliance should be accredited to the ISO standard and 
producers should use laboratories which hold that accreditation to perform their 








The ACMD make the following recommendations to provide a legal framework to control 
the amounts of phytocannabinoids in consumer CBD products under the MDA.   
 
Recommendation 1  
That the total dose of ∆9-THC (including ∆9-THCA, as calculated using Equation 1) and all 
other controlled phytocannabinoids in consumer CBD products be controlled. The dose of 
each controlled phytocannabinoid should not exceed 50 micrograms (µg) per unit of 
consumption. 
 
Note 1. A unit of consumption or ‘single serving’ being defined as the typical quantity of a 
CBD product consumed on one occasion. 
 
Lead organisations: Home Office. 
 
Measure of impact: This will have been implemented by a change to the Misuse of 
Drugs Regulations 2001 (MDR).  
 
Recommendation 2  
That regulatory authorities ensure that any consumer CBD product permitted to market has 
limits on the content of controlled phytocannabinoids such that the dose of ∆9-THC 
(including its precursor ∆9-THCA) and of each of the other controlled phytocannabinoids 
does not exceed 50 micrograms (µg) per unit of consumption. 
Lead organisations: Home Office liaising with the appropriate regulatory authorities and 
their devolved counterparts where appropriate:  
• Food Standards Agency (FSA) 
• Department for Business, Energy and Industrial Strategy (BEIS): (Office for Product 
Safety and Standards (OPSS) 
• Department for Health and Social Care (DHSC): Office for Health Improvement and 
Disparities (OHID); and,  
• Department for Environment Food and Rural Affairs (DEFRA) (UK REACH)  
 
Measure of impact: Evidence of compliance with the permitted levels. The ACMD 
advise another analysis of the controlled phytocannabinoid content of consumer CBD 
products is performed by Dstl two years after the implementation of the regulations to check 




Recommendation 3  
A further inter laboratory comparison trial (ring trial) should be commissioned specifically to 
support the capability of testing laboratories to detect controlled phytocannabinoids below 
the recommended maximum levels in a representative range of consumer CBD products  
Lead organisations:  Home Office 
Measure of impact:  An assessment of whether the necessary level of accuracy can 
be achieved in practice. 
 
Recommendation 4  
That development of more accurate testing for controlled phytocannabinoids is supported 
(as outlined in Notes 1 – 3 below) to allow testing capabilities to develop and be fully 
regulated.  
Note 1: Standardised protocols should be developed for the extraction, separation and 
quantification of controlled cannabinoids (and their precursor acids) from consumer CBD 
products. These must be of sufficient reproducibility and sensitivity to be appropriate for the 
measurement of the level of controlled phytocannabinoids as recommended in this report.  
Note 2: As chemical reference standards are not currently commercially available for all 
controlled phytocannabinoids, suppliers of chemical reference materials should be 
encouraged to produce certified standards for those controlled cannabinoids for which 
standards are not currently available. 
Note 3: ACMD supports the recommendation from the Dstl report (Defence Science and 
Technology Laboratory report, 2020b) that the analytical methods used should be 
accredited to ISO 17025:2017 to ensure appropriate method validation, quality control and 
independent assessment of the methods. 
Lead organisations: Home Office. 
Measure of impact:  An increase in the number of laboratories that have been, or are 
in the process of becoming, accredited to demonstrate their capability to quantify ∆9-THC 






Annex A List of abbreviations used in this report 
 
Abbreviation Name 
∆9-THCA trans-delta-9-tetrahydrocannabinol-C5 acid 
∆9-THCA-A/B trans-delta-9-tetrahydrocannabinol-C5 Acid 2/4-carboxylic acid 
ACMD Advisory Council on the Misuse of Drugs 
BEIS Department for Business, Energy & Industrial Strategy 
CB1 receptor Cannabinoid type-1 receptor 
CB2 receptor Cannabinoid type-2 receptor 
CBC(A) Cannabichromene (Acid) 
CBD(A) Cannabidiol (Acid) 
CBG(A) Cannabigerol (Acid) 
CBN Cannabinol-C5 
DEFRA Department for Environment, Food and Rural Affairs 
DHSC The Department of Health and Social Care 
Dstl  Defence Science and Technology Laboratory 
FSA Food Standards Agency 
g Gram (weight) 
GC Gas Chromatography 
INCB International Narcotics Control Board 
LC Liquid Chromatography 
LoQ Limit of Quantification 
MDA Misuse of Drugs Act 1971 
MDR Misuse of Drugs Regulations 2001 
µg Microgram (0.000001 g = 1 x 10-6 g) 
mg Milligram (0.001 g = 1 x 10-3 g) 




MS-MS Tandem Mass Spectrometry 
OHID 
Office for Health Improvement and Disparities (formerly Public Health 
England) 
OPSS Office for Product Safety and Standards 
PSA Psychoactive Substances Act 2016 
SCRA Synthetic cannabinoid receptor agonists 
THC(A) Tetrahydrocannabinol (Acid) 
THCV Delta-9-Tetrahydrocannabivarin 
UK United Kingdom 
UK REACH Registration, Evaluation, Authorisation and Restriction of Chemicals 
UNODC United Nations Office on Drugs and Crime 




Annex B  Quality of Evidence 
 
Range of evidence 
 
Evidence gathered was considered in line with the ACMD’s ‘Standard Operating  
Procedure for using evidence in ACMD reports’ (ACMD, 2020). 
 
The report mainly referred to peer-reviewed scientific literature, government reports (UK 
and international), a call for evidence carried out by the ACMD (ACMD, 2021) and past 
ACMD reports. To understand the CBD market better, the Working Group received 
information from representatives from the Defence Science and Technology Laboratory 
(Dstl), the Government Chemist’s Team and representatives of industry. To understand the 
current legislation the Working Group had discussions with representatives from the Home 
Office, Food Standards Agency, Department for Business Energy and Industrial Strategy, 
the Department for Health and Social Care and the Department for Environment, Food and 
Rural Affairs. 
 
Quality of this Evidence 
 
There is limited literature about the controlled phytocannabinoids outside of ∆9-THC, 
however, there is evidence about the effects of ∆9-THC on humans.  
 
The Dstl reports gave good insight into the theoretical testing capacity of different methods, 
however, there was poor evidence about what could be achieved in practice (Defence 
Science and Technology Laboratory report, 2020a), (Defence Science and Technology 
Laboratory report, 2020b). This was further complicated by the need to extract from 
different matrices. The main evidence for the practical capacity for the analytics industry to 
test was the Government Chemist’s Team ring trial (Government Chemist's Team, 2021). 
 
The call for evidence carried out by the ACMD received 14 responses, mainly from industry 
but also interested members of the public. The quality of this evidence ranged from full 
reports backed up by peer-reviewed literature to subjective opinion. This was all considered 
by the Working Group. The Working Group also considered the small sample size. 
 
Evidence relevant to recommendations 
 
Whilst there was evidence about the quantity of ∆9-THC to produce a psychoactive effect 
this was when only consuming ∆9-THC not with other phytocannabinoids. However, the 
international comparison gave the Working Group confidence in Recommendation 1 and 
Recommendation 2. The results of the ring trial and the Dstl reports back the need for 




Annex C Analytical Methods 
 
The following is a summary table of analytical techniques taken from the Defence Science 












s (w/w %) 




Low sensitivity, cannot measure 
thermally labile acid form 
cannabinoids without derivatisation 








High cost. Cannot measure 
thermally labile acid form 
cannabinoids without derivatisation 
(decarboxylation occurs in hot GC 
inlet). 
0.46 0.000046 






High cost. Trace level conversion of 
CBD to THC possible under acidic 
conditions. Difficult to disprove 
because of lack of THC-free matrix. 
0.375 0.0000375 
(3.75 x 10-5) 
GC-MS/MS  Very high 
selectivity and 
sensitivity 
Very high cost, derivatisation 
required for highest sensitivity can 
be inconsistent and compromise 
quantitative analysis. Expensive 
isotopically labelled reference 
chemicals required for accurate 
quantitation. 
0.0011 0.00000011 
(1.1 x 10-7) 








Less selective than mass 
spectrometry and subject to matrix 
effects in complex samples. 
27.59 0.002759 





May requires longer methods to 
facilitate proper resolution between 
compounds that co-elute as a result 
of less MS selectivity than tandem 
mass spectrometry. 
N/A N/A 
LC-MS/MS  Very high 
selectivity and 
sensitivity 
Very high cost, matrix matching 
important for quantitative analysis 
and assessment of ion suppression 
in validation. Expensive isotopically 
labelled reference chemicals 
required for accurate quantitation. 
0.004 0.0000004 
(4 x 10-7) 









A gas-chromatograph comprises a long, narrow, tube coated on the inside with a thin film of 
non-volatile liquid, known as the stationary phase. The tube, referred to as the analytical 
column, is coiled and heated in an oven. A small aliquot of a solvent extract is injected into 
one end of the heated column via a heated inlet which immediately vaporises the extract. A 
carrier gas, typically helium, hydrogen or nitrogen, flows through the column taking with it 
the evaporated extract. The compounds present in the extract will emerge from the other 
end of the column at different times (known as retention times) depending on their volatility 
and interaction with the stationary phase. Compounds are identified by comparing their 
retention time with those of reference standards. 
 
GC is only suitable for compounds that are soluble and can be vaporised or converted to a 
volatile compound by derivatisation. It is not suitable for thermally labile compounds (e.g. 
THCA). 
 
Several different methods can be used to detect the separated compounds as they emerge 
from the end of the GC column. 
 
Gas-chromatography with Flame Ionisation detection (GC-FID) 
 
The effluent from the end of the column is passed through a small hydrogen-air flame. 
When a compound emerges from the column and burns in the flame it produces ions which 
are detected as an electrical current. The current produced is proportional to the amount of 
compound being burnt. GC-FID can therefore be used to quantify the concentration of a 
compound in the extract by comparison of a reference standard of known concentration. 
However, the specificity of GC-FID is limited, as compounds are only identified by their 
retention time. 
 
Gas-chromatography with Mass Spectrometry (GC-MS) 
 
Mass spectrometry is a powerful analytical technique that can be used to identify 
compounds by elucidating their chemical structure. In GC-MS the effluent from the GC 
column enters the mass spectrometer where molecules of any compounds emerging from 
the GC column are bombarded with a beam of electrons. The collision will remove an 
electron from some of the molecules producing positively charged particles (ions) and some 
of these charged particles will break up into positively charged fragments of various sizes. A 
simple analogy would be a china cup which will break up into several characteristic pieces 
(handle, base, rim, etc) when dropped on the floor. The mass spectrometer then uses 
electric and magnetic fields in a ‘mass analyser’ to measure the size (“weight”) of each of 
the positively charged particles. An ion detector such as an electron multiplier is then used 
to detect the charged particles of each size. The results can be displayed as a mass 
spectrum on a chart showing the relative signal intensities of the detected ions. The mass 
spectrum can then be used to identify the parent compound by comparison with a library of 
mass spectra of reference compounds. The fragmentation pattern can also be used to 
elucidate the chemical structures of unknown compounds. The detector response for each 
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fragment size is proportional to the concentration of the parent compound and therefore 
GC-MS can also be used to quantify the concentration of the compound in the extract. 
 
Gas-chromatography with Tandem Mass Spectrometry (GC-MS/MS) 
 
The tandem mass spectrometer consists of two mass analysers coupled together. Sample 
extracts are analysed in the same way as GC-MS but selected charged particles of a 
particular size from the first mass analyser are made to split into smaller fragment ions. The 
size and abundance of these ‘daughter ions’ are then measured in a second mass analyser. 
These mass transition from a selected fragment ion to daughter ions provides greater 
confidence in the identification of unknown compounds. GC-MS/MS is useful for complex 
matrices and low-level quantitation. 
 
Liquid Chromatography (LC) 
 
Liquid chromatography, also referred to a high pressure or high-performance 
chromatography (HPLC), is based on the partition of compounds between a solid stationary 
phase and a liquid mobile phase. It comprises a chromatography column made from a short 
stainless-steel tube (typically 30-300mm long and 6mm outside diameter) packed with very 
small particles (typically 5μm diameter) of a stationary phase, such as silica or chemically 
modified silica. A mobile phase, typically a mixture of solvents such as water and 
acetonitrile and/or methanol, is forced through the column at a regulated rate using a high-
pressure pump. A small aliquot of the solvent extract is injected into the mobile phase which 
carries the sample onto the column. Compounds present in the extract will emerge from the 
end of the column at different times (known as the retention time) depending on the 
strength of their attraction to the stationary phase. 
 
Advantages of LC are that it can be used for non-volatile and thermally labile compounds, 
such as THCA, which are not suitable for GC analysis. 
 
Several different methods can be used to detect the separated compounds as they emerge 
from the end of the LC column. 
 
Liquid Chromatography with UV (LC-UV) 
 
LC-UV is useful for the detection of compounds which have an absorption spectrum in the 
ultra-violet (UV) region such as those that contain pi-bonds as found in aromatic rings, 
carbonyl groups and double bonds. The phytocannabinoids all contain an aromatic ring so 
can be analysed by LC-UV. 
 
In an LC-UV detector the effluent from the LC column passes through a transparent flow 
cell located in a beam of UV light of a fixed wavelength. The mobile phase does not absorb 
much UV light so when a compound emerges from the column it will absorb some of the UV 
light producing a peak in the chromatogram. Early LC-UV detectors used a mercury lamp 
for the light source which emits UV light at a fixed wavelength of 254 nm. More recently LC-
UV detectors use a deuterium discharge lamp as it provides an almost continuous spectrum 
of light over the 190–400 nm range. A diffraction grating is then used to select a suitable 
wavelength for the compounds being analysed. In both cases, the amount of UV light 
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passing through the flow cell is measured using a photodiode and compared to the amount 
of UV light entering the flow cell.  
 
The specificity of LC-UV detection at a fixed wavelength is limited as many compounds 
have an absorption in the ultraviolet region so compounds are only identified by their 
retention time. 
 
The sensitivity of UV detection depends on how much UV light a standard solution of the 
compound absorbs (the molar extinction coefficient). The amount of UV light absorbed is 
proportional to concentration so LC-UV can be used for the quantitation of compounds by 
comparing the response with reference standards of known concentration. 
 
Liquid Chromatography with Photodiode Array/Diode Array Detection (LC-UV/DAD) 
 
The specificity of the LC-UV detector is greatly improved by measuring the absorption of UV 
light at more than one wavelength. In a (photo)diode array detector (DAD or PAD) light from 
the deuterium discharge lamp is shone directly onto the flow cell and UV light passing 
through the flow cell is dispersed by a diffraction grating (in the same way that a prism splits 
visible light into different colours). The amount of dispersed UV-light at each wavelength is 
measured simultaneously using an array of, typically 1024, photodiodes. The diode array 
detector can therefore record the complete UV spectrum of each compound emerging from 
the LC column, which considerably enhances the specificity. However, a disadvantage of 
LC-UV/DAD is that it is less sensitive than the fixed wavelength LC-UV detector. This is 
because the photodiodes in a diode array are much smaller than the single photodiodes 
used in a fixed wavelength UV detector and so receive less light. 
 
Liquid Chromatography with Mass Spectrometry and Tandem Mass Spectrometry 
(LC-MS and LC-MS/MS) 
 
These techniques are analogous to the corresponding GC-MS and GC-MS/MS techniques, 
the main difference being the interface between the LC column and the inlet of the Mass 
Spectrometer. The development of LC-MS was limited for many years due to the 
incompatibility of the MS electron beam ionisation process, which takes place in a vacuum, 
with a continuous liquid stream emerging from the LC column. This problem was overcome 
in the 1980’s by the development of the electrospray ion source. The effluent from the LC 
column passes through a metal capillary maintained at a high voltage (3 – 5kV). The liquid 
is then nebulised at the tip of the capillary to form a fine spray of charged droplets. The 
solvent in these droplets rapidly evaporates and the residual electrical charge is transferred 
to the analyte to create molecular ions. These ions are then transferred into the high 
vacuum of the mass spectrometer via a series of small apertures and electric fields. 
 
Electrospray ionisation (ESI) transfers relatively little energy to the analyte molecules, so 
little fragmentation occurs. LC-MS is therefore less specific than GC-MS as the mass 
spectrum contains less structural information than for GC-MS.  
 
A further issue with ESI is ion suppression, which can occur when more than one 
component elutes simultaneously and are present in the same spray droplets. This can 
result in the electric charge being preferentially transferred to one of the components, 
suppressing the ions of the other component(s). This can be a limitation on the sensitivity of 
LC-MS and can lead to unreliable quantitative results. Stable isotope labelled internal 
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reference standards can be used to overcome the quantitation problem, otherwise sample 
preparation methods need to be developed to minimise the effects of ion suppression. 
 
Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) 
 
In tandem mass spectrometry, the ions produced by ESI can be induced to undergo more 
extensive fragmentation by collisions with an inert gas such as nitrogen or argon in a 
collision cell located between two mass analysers. The fragments can then be 
characterised in the second mass analyser. This is analogous to the GC-MS/MS technique 
and provides greater confidence in identifications.
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Annex D Controlled Phytocannabinoids information  
 
This table contains information on the 12 controlled phytocannabinoids identified in the ACMD’s Phytocannabinoids report (ACMD, 2016) with 
additional technical information provided to us by the Laboratory of Government Chemist and the Working Group. 
 






































































































































































ether, CBNM-C5  
 
 
41935-92-6 No Unknown N/A Yes 
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